Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Hyper-CVAD plus ofatumumab als eerstelijnsbehandeling bij Ph-negatieve B-cel ALL
aug 2020 | Leukemie